DK2493930T3 - Forbedrede anti-humane fractalkinantistoffer og anvendelser deraf. - Google Patents
Forbedrede anti-humane fractalkinantistoffer og anvendelser deraf. Download PDFInfo
- Publication number
- DK2493930T3 DK2493930T3 DK10826929.1T DK10826929T DK2493930T3 DK 2493930 T3 DK2493930 T3 DK 2493930T3 DK 10826929 T DK10826929 T DK 10826929T DK 2493930 T3 DK2493930 T3 DK 2493930T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- artificial sequence
- binding fragment
- seq
- thr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (31)
1. Antifractalkinantistof eller fractalkinbindende fragment deraf, hvori antistoffet eller det fractalkinbindende fragment deraf omfatter en tung kæde og en let kæde, hvori den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 26, og den lette kæde omfatter aminosyresekvensen ifølge NO: 27, den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 36, og den lette kæde omfatter aminosyresekvensen ifølge NO: 38, den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 36, og den lette kæde omfatter aminosyresekvensen ifølge NO: 44, den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 37, og den lette kæde omfatter aminosyresekvensen ifølge NO: 38, den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 37, og den lette kæde omfatter aminosyresekvensen ifølge NO: 44, eller den tunge kæde omfatter aminosyresekvensen ifølge SEQ ID NO: 37, og den lette kæde omfatter aminosyresekvensen ifølge NO: 45.
2. Antistof ifølge krav 1, hvori antistoffet er et intakt antistof.
3. Antistof eller fractalkinbindende fragment deraf ifølge krav 1 eller 2, hvori antistoffet eller det fractalkinbindende fragment humaniseres.
4. Antistof eller fractalkinbindende fragment deraf ifølge krav 1, 2 eller 3, hvori antistoffet eller det fractalkinbindende fragment er kimært.
5. Antistof eller fractalkinbindende fragment deraf ifølge krav 4, hvori antistoffet omfatter en tung kæde og en let kæde, hvori antistoffets variable tunge kæde-domæne omfatter aminosyresekvensen ifølge SEQ ID NO: 26, og hvori antistoffets variable lette kæde-domæne omfatte aminosyresekvensen ifølge SEQ ID NO: 27.
6. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-4, hvori antistoffet eller det fractalkinbindende fragment heraf omfatter en tung kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 37, og en let kæde, der omfatter aminosyresekvensen ifølge SEQ ID NO: 44 .
7. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-6, der omfatter en human konstant region.
8. Antistof eller fractalkinbindende fragment deraf ifølge krav 7, der omfatter en konstant region af en IgG-isotype.
9. Antistof eller fractalkinbindende fragment deraf ifølge krav 8, der omfatter en konstant region af IgG2-isotypen.
10. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-9, der omfatter en muteret Fc-region således, at antistoffet har reduceret antistofafhængig cellemedieret cytotoksicitet og/eller komplementaktivering.
11. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af krav 1 eller kravene 3 til 9, hvori det fractalkinbindende fragment er valgt fra den gruppe, der består af et Fab, et Fab' , et F(ab')2 og et Fv, og hvori det fractalkinbindende fragment bevarer bindingsspecificiteten til fractalkin.
12. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-11, hvori antistoffet hæmmer bindingen mellem fractalkin og CX3CR1.
13. Antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-12 til anvendelse ved behandling af en inflammatorisk lidelse, hvori den inflammatoriske lidelse er ulcerativ colitis, Crohns sygdom eller rheumatoid arthritis.
14. Farmaceutisk sammensætning, der omfatter et antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-13.
15. Farmaceutisk sammensætning ifølge krav 14 til anvendelse ved behandling af en inflammatorisk lidelse, hvori den inflammatoriske lidelse er ulcerativ colitis, Crohns sygdom eller rheumatoid arthritis.
16. Farmaceutisk sammensætning ifølge krav 14 eller 15, hvori sammensætningen desuden omfatter en bærer.
17. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 14-16, hvori sammensætningen desuden omfatter et yderligere terapeutisk middel.
18. Nukleinsyre, der koder for et antistof eller fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-13.
19. Vektor, der omfatter nukleinsyren ifølge krav 18.
20. Vektor ifølge krav 19, hvori vektoren er en ekspressionsvektor.
21. Værtscelle, der omfatter én eller flere vektorer ifølge krav 19 eller 20.
22. Værtscelle ifølge krav 21, hvori værtscellen omfatter en første og anden vektor, idet den første vektor omfatter en nukleinsyre, der koder for en tung kæde, og den anden vektor omfatter en nukleinsyre, der koder for en let kæde af et antistof eller et fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-13.
23. Værtscelle ifølge krav 22, hvori ekspression af den tunge og lette kæde i værtscellen producerer et antistof eller et fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-13.
24. Værtscelle ifølge et hvilket som helst af kravene 21-23, hvori værtscellen er prokaryotisk.
25. Værtscelle ifølge et hvilket som helst af kravene 21-23, hvori værtscellen er eukaryotisk.
26. Værtscelle ifølge krav 25, hvori værtscellen er en pattedyrs celle.
27. Værtscelle ifølge krav 26, hvori cellen er en CHO-celle eller en NSO-celle.
28. Fremgangsmåde til fremstilling af et antifractalkinantistof eller et fractalkinbindende fragment deraf, hvilken fremgangsmåde omfatter (a) ekspression af vektoren ifølge et hvilket som helst af kravene 19 eller 20 i en egnet værtscelle og (b) udvinding af antistoffet eller det fractalkinbindende fragment deraf.
29. Fremgangsmåde ifølge krav 28, hvori antistoffet eller det fractalkinbindende fragment deraf udskilles af værtscellen i dyrkningsmedier.
30. Fremgangsmåde ifølge krav 29, hvori antistoffet eller det fractalkinbindende fragment deraf oprenses til mindst 95 % eller mere i forhold til det antistofholdige dyrkningsmedium.
31. Anvendelse af et antistof eller et fractalkinbindende fragment deraf ifølge et hvilket som helst af kravene 1-13 til fremstilling af et lægemiddel til anvendelse ved behandling af en inflammatorisk lidelse, hvorved den inflammatoriske lidelse er ulcerativ colitis, Crohns sygdom eller rheumatoid arthritis .
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25652109P | 2009-10-30 | 2009-10-30 | |
| PCT/JP2010/069653 WO2011052799A1 (en) | 2009-10-30 | 2010-10-28 | Compositions and methods for treating inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2493930T3 true DK2493930T3 (da) | 2018-12-17 |
Family
ID=43922220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10826929.1T DK2493930T3 (da) | 2009-10-30 | 2010-10-28 | Forbedrede anti-humane fractalkinantistoffer og anvendelser deraf. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8932592B2 (da) |
| EP (1) | EP2493930B1 (da) |
| JP (2) | JP5631991B2 (da) |
| KR (2) | KR102099596B1 (da) |
| CN (1) | CN102597003B (da) |
| AR (2) | AR078796A1 (da) |
| AU (1) | AU2010312408B2 (da) |
| BR (1) | BR112012010266A2 (da) |
| CA (1) | CA2778895C (da) |
| CL (2) | CL2012001143A1 (da) |
| CY (1) | CY1121167T1 (da) |
| DK (1) | DK2493930T3 (da) |
| ES (1) | ES2698389T3 (da) |
| HR (1) | HRP20181973T1 (da) |
| HU (1) | HUE041952T2 (da) |
| IL (1) | IL219470A (da) |
| JO (1) | JO3437B1 (da) |
| LT (1) | LT2493930T (da) |
| MX (1) | MX2012005052A (da) |
| MY (1) | MY158481A (da) |
| NZ (1) | NZ599779A (da) |
| PE (1) | PE20121645A1 (da) |
| PL (1) | PL2493930T3 (da) |
| PT (1) | PT2493930T (da) |
| RS (1) | RS58142B1 (da) |
| RU (1) | RU2569109C2 (da) |
| SI (1) | SI2493930T1 (da) |
| TW (1) | TWI414308B (da) |
| UA (1) | UA105073C2 (da) |
| WO (1) | WO2011052799A1 (da) |
| ZA (1) | ZA201203002B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9415118B2 (en) * | 2013-03-13 | 2016-08-16 | Novartis Ag | Antibody drug conjugates |
| PL3221363T3 (pl) | 2014-11-21 | 2021-01-11 | Bristol-Myers Squibb Company | Przeciwciała przeciwko cd73 i ich zastosowanie |
| CN113929770A (zh) | 2014-11-21 | 2022-01-14 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| EP3159007A1 (en) | 2015-10-19 | 2017-04-26 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating rheumatoid arthritis |
| JP2017154975A (ja) * | 2016-02-29 | 2017-09-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | クローン病を治療するための医薬組成物 |
| JP2018070473A (ja) * | 2016-10-26 | 2018-05-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 関節リウマチを治療するための医薬組成物 |
| JP2018177701A (ja) * | 2017-04-14 | 2018-11-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | クローン病を治療するための医薬組成物 |
| WO2020214166A1 (en) * | 2019-04-17 | 2020-10-22 | The Governors Of The University Of Alberta | Treatment of autoimmune liver disease |
| US20220205980A1 (en) | 2019-04-23 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Biomarker for rheumatoid arthritis treatment |
| CN113087795A (zh) * | 2019-12-23 | 2021-07-09 | 上海普铭生物科技有限公司 | 针对趋化因子cx3cl1的抗体及其应用 |
| US20230338522A1 (en) | 2020-10-30 | 2023-10-26 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US6096312A (en) | 1995-06-30 | 2000-08-01 | Mochida Pharmaceutical Co., Ltd. | Agent for suppressing a reduction of CD4+ lymphocytes |
| AU724856B2 (en) | 1995-06-30 | 2000-10-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| US6114507A (en) | 1995-06-30 | 2000-09-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| US6566503B2 (en) | 1996-01-24 | 2003-05-20 | Schering Corporation | Mammalian CX3C chemokine |
| ATE389018T1 (de) | 1996-01-24 | 2008-03-15 | Schering Corp | Cx3c chemokin-gene von säugetieren |
| US7115379B1 (en) | 1996-01-24 | 2006-10-03 | Schering Corporation | Anti-mammalian CX3C cytokine antibodies |
| US6548654B1 (en) | 1996-01-24 | 2003-04-15 | Schering Corporation | DNA encoding mammalian CX3C chemokine genes |
| US6043086A (en) * | 1996-05-07 | 2000-03-28 | Millenium Biotherapeutics, Inc. | Neurotactin and uses therefor |
| CA2253864A1 (en) | 1996-05-07 | 1997-11-13 | Millennium Biotherapeutics, Inc. | Neurotactin and uses therefor |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| AU771946B2 (en) | 1998-08-31 | 2004-04-08 | Oregon Health And Science University | Prevention of cell migration initiation with CMV US28 receptor antagonists |
| JP2001218581A (ja) | 1999-11-30 | 2001-08-14 | Eisai Co Ltd | モノクローナル抗体の作製法 |
| US6677321B1 (en) | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
| AU2000273378A1 (en) | 2000-02-18 | 2001-08-27 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| US8647612B2 (en) | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US20020192212A1 (en) | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| JP4263391B2 (ja) | 2001-03-19 | 2009-05-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用 |
| SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| DE60233336D1 (de) | 2001-08-30 | 2009-09-24 | Chemocentryx Inc | Bicyclische verbindungen als hemmer der chemokin-bindung an us28 |
| JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
| PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
| EP1520586A1 (en) | 2003-09-30 | 2005-04-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases |
| EP1671648A4 (en) | 2003-10-02 | 2009-07-08 | Eisai R&D Man Co Ltd | PREVENTION AND TREATMENT OF GVHD |
| JP2007507494A (ja) | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン |
| WO2006033386A1 (ja) * | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
| US8518401B1 (en) | 2004-10-29 | 2013-08-27 | Eisai R&D Management Co., Ltd. | Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| ES2410886T3 (es) | 2006-10-26 | 2013-07-03 | Janssen Biotech, Inc. | Métodos para la adaptación al ser humano de anticuerpos monoclonales |
| EP2197911A2 (en) * | 2007-09-14 | 2010-06-23 | Amgen Inc. | Homogeneous antibody populations |
-
2010
- 2010-10-27 JO JOP/2010/0374A patent/JO3437B1/ar active
- 2010-10-28 HU HUE10826929A patent/HUE041952T2/hu unknown
- 2010-10-28 SI SI201031803T patent/SI2493930T1/sl unknown
- 2010-10-28 PE PE2012000580A patent/PE20121645A1/es active IP Right Grant
- 2010-10-28 AR ARP100103947A patent/AR078796A1/es active IP Right Grant
- 2010-10-28 RU RU2012122203/10A patent/RU2569109C2/ru active
- 2010-10-28 NZ NZ599779A patent/NZ599779A/en not_active IP Right Cessation
- 2010-10-28 MX MX2012005052A patent/MX2012005052A/es active IP Right Grant
- 2010-10-28 WO PCT/JP2010/069653 patent/WO2011052799A1/en active Application Filing
- 2010-10-28 US US13/504,742 patent/US8932592B2/en active Active
- 2010-10-28 JP JP2012520621A patent/JP5631991B2/ja active Active
- 2010-10-28 MY MYPI2012001924A patent/MY158481A/en unknown
- 2010-10-28 EP EP10826929.1A patent/EP2493930B1/en active Active
- 2010-10-28 KR KR1020167014386A patent/KR102099596B1/ko active IP Right Grant
- 2010-10-28 KR KR1020127014048A patent/KR101627605B1/ko active IP Right Grant
- 2010-10-28 DK DK10826929.1T patent/DK2493930T3/da active
- 2010-10-28 TW TW099137131A patent/TWI414308B/zh active
- 2010-10-28 PL PL10826929T patent/PL2493930T3/pl unknown
- 2010-10-28 BR BR112012010266A patent/BR112012010266A2/pt not_active Application Discontinuation
- 2010-10-28 ES ES10826929T patent/ES2698389T3/es active Active
- 2010-10-28 LT LTEP10826929.1T patent/LT2493930T/lt unknown
- 2010-10-28 CN CN201080049138.0A patent/CN102597003B/zh active Active
- 2010-10-28 CA CA2778895A patent/CA2778895C/en active Active
- 2010-10-28 AU AU2010312408A patent/AU2010312408B2/en active Active
- 2010-10-28 PT PT10826929T patent/PT2493930T/pt unknown
- 2010-10-28 UA UAA201206559A patent/UA105073C2/uk unknown
- 2010-10-28 RS RS20181424A patent/RS58142B1/sr unknown
-
2012
- 2012-04-24 ZA ZA2012/03002A patent/ZA201203002B/en unknown
- 2012-04-29 IL IL219470A patent/IL219470A/en active IP Right Grant
- 2012-04-30 CL CL2012001143A patent/CL2012001143A1/es unknown
-
2014
- 2014-09-18 JP JP2014189668A patent/JP2015027304A/ja not_active Abandoned
-
2015
- 2015-01-15 CL CL2015000114A patent/CL2015000114A1/es unknown
-
2017
- 2017-09-15 AR ARP170102555A patent/AR109533A2/es unknown
-
2018
- 2018-11-23 HR HRP20181973TT patent/HRP20181973T1/hr unknown
- 2018-11-29 CY CY20181101274T patent/CY1121167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2493930T3 (da) | Forbedrede anti-humane fractalkinantistoffer og anvendelser deraf. | |
| AU2016200412A1 (en) | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof | |
| JP2016029027A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| MX2012011629A (es) | Proteinas de union a tnf-alfa. | |
| US20120282254A1 (en) | Cd127 binding proteins | |
| JP6236478B2 (ja) | 血清アミロイドｐ成分に特異的な抗原結合タンパク質 | |
| US9181332B2 (en) | Anti-A(β) oligomer humanized antibody | |
| WO2011053707A1 (en) | Antibodies to receptor for advanced glycation end products (rage) and uses thereof | |
| JP5692073B2 (ja) | 抗アミロイドβオリゴマーヒト化抗体 | |
| CN115697393A (zh) | 抗PHF-tau抗体及其用途 | |
| WO2011080050A2 (en) | Binding molecules | |
| CN114375305A (zh) | Cr2结合蛋白及其在医学疗法中的用途 | |
| EA040834B1 (ru) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К IL-23p19 ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, ЕГО ПРИМЕНЕНИЕ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ УКАЗАННОЕ АНТИТЕЛО |